ABSTRACT
INTRODUCTION
Lyme disease-also known as Lyme borreliosis (LB)-can be caused in humans by at least three genospecies of the Borrelia burgdorferi sensu lato complex, B. burgdorferi, B. garinii and B. afzelii.
In the USA and southern Canada, B. burgdorferi sensu stricto cause flu-like illness at early disease stages that can later develop to Lyme arthritis and other long-term complications [1] . LB is initiated by the bacterial infection following a bite from an infected Ixodes scapularis or Ixodes pacificus blacklegged tick. Presently, LB is the most common vector-borne disease in North America and Europe [1] . Over 30,000 cases are reported in the US annually [2] . However, actual prevalence estimates are thought to be at least ten times as high because of underreporting [3] . In Canada, an increased incidence of LB by *six-fold-from 128 to 707 cases-was noted between 2009 and 2015 [4] . LB patients treated with antibiotics in the early stages do not develop detectable antibodies [6, 7] . Most patients who are not treated in early LB go on to suffer early disseminated LB with manifestation of neuroborreliosis (e.g., Bell's palsy and meningitis), multiple EM lesions and, less commonly, myocarditis [8] [9] [10] . These stages and characteristics are based on the guidelines developed by the Infectious Diseases Society of America (IDSA) [9] . The IDSA LB guidelines have been delisted recently by the US National Guideline Inflammation, induced by either the spirochete or its antigens in the affected tissues, is thought to play a major role in LB pathogenesis at both the early and late disease stages [12, 13] . Early inflammatory responses distinguish patients from healthy controls and diverge from those of other diseases with overlapping clinical features [12] . The final outcome of infection, however, is dependent on the intricate interaction between the pathogen and the host immune response [12, 13] . Therefore, elucidating the extent of alteration in the host inflammatory and immunological pathways at the early stages of host-pathogen interaction may provide an insight into the potential mechanisms rendering B. burgdorferi-infected subjects susceptible to disseminated LB and, perhaps, the later development of post-treatment Lyme disease syndrome (PTLDS). It may also facilitate characterizing an array of biomarkers for various disease stages that can serve as targets for new diagnostic techniques and assist in development of therapies [13] . Early LB is usually diagnosed by the recognition of an EM skin lesion as detectable antibodies are not present at the very early disease stage in many patients [14] .
However, other skin lesions can be confused with EM, e.g., southern tick-associated rash illness, tick-bite hypersensitivity reactions and some cutaneous fungal infections [6, 15, 16] . Several laboratory-based molecular and immunologic approaches for detection of B.
burgdorferi sensu lato and diagnosis of LB have been developed over the past 3 decades [17] .
These included tests for direct detection of the spirochete, the detection of specific antibodies using whole-cell lysates, recombinant antigens or peptide antigens in enzyme immunoassays (EIA), or nucleic acid amplification from peripheral blood samples [for review, see 17].
At early disease stages, detection of B. burgdorferi antibodies or using PCR-based approaches in peripheral blood samples were proved unsatisfactory [17] . Currently, an antibody-based diagnostic method is widely utilized in clinical practice, and a two-tier approach for serologic testing-using EIA followed by immunoblotting for IgM and IgG-is recommended [18] . The approach is based on antibody detection and is highly specific and sensitive in patients with late manifestations of LB but exhibits a moderate sensitivity (29%-40%) in those in early disease [14, 17] . Recent evidence, however, suggests that serological testing can be poor, even in LB patients who were culture-positive for B.
burgdorferi [19] . The current status of LB serological testing emphasizes the need for more sophisticated approaches such as omics technologies at all disease stages.
These limitations, together with the possible misdiagnosis of EM lesions by clinicians, necessitate the development of an improved test for the detection of LB, particularly at the early disease stages. Non-antibody-based methodologies have been proposed as a novel approach for the detection of spirochetes or assessing the responses to the pathogen [17] . If these methods improve the established diagnostic tests by having higher specificity and sensitivity, they will enhance patient management and may obviate repeated testing and help alleviate controversies and subjectivities over LB diagnosis [14] .
Driven by marked improvement in analytical platforms, increasing resolution and sensitivity, high-throughput capabilities and reduced cost, the use of omics approaches has grown exponentially in recent years [20] . Omics methodologies have allowed elucidating mechanisms of pathogenesis for numerous disease-causing agents and facilitated discovery of disease biomarkers (biosignature) and response to prevention or therapy [20] [21] [22] [23] [24] . It has the potential to assess the effects of a particular factor on many molecules including thousands of mRNAs, proteins, metabolites, imprinting of genes, alternative splicing of mRNAs and mutations [22] . The present article provides a comprehensive evaluation and review of the omics technologies employed to study biomarkers and biosignatures of early LB stages in human. The contributions of the individual omics analytical platform to understanding disease etiology is presented, with a goal to provide a background on their respective abilities in identifying a panel of inflammatory mediators as biomarkers for early disease detection and diagnosis.
Compliance with Ethics Guidelines
This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by the author. [43] . Levels of IL-1b were higher in synovial fluid and tissue of patients with post-treatment Lyme arthritis compared to their counterparts who recovered after the antibiotic treatment [42] . Although the role of IL-1b is yet to be fully understood and is controversial-together with other cytokines-at post infection and PTLDS
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[11], it was thought to be related to the induction of a IL-17/Th17 response against the spirochetes and the subsequent synthesis of IL-22 [40] . Thus, IL-17/Th17 response augments the immune activation upon microbial recognition [40] with IL-1b controlling the production of IL-17A, IL-17F, IL-17AF, IL-21, IL-22 and IL-26. These products of Th17, particularly IL-22, are critical factors in the development of the Borrelia antigen-induced arthritis in animal models [44, 45] . IL-1b blockade was, therefore, associated with a disrupted Th17 response and IL-17 levels [35] .
IL-22 (and IFN-c) was detected in the skin of individuals with EM [46] , and IL-17 was found in higher levels in synovial cells from Lyme arthritis patients [47] and patients with neuroborreliosis [48] than subjects with earlier disease stages. were also elevated in cerebrospinal fluid from patients with neuroborreliosis [52] . Studies in Borrelia-infected mice [53] and patients with neuroborreliosis [54] have shown that a rapid IFN-c response provides a more beneficial outcome than a slower or no responses. However, this instantaneous response was associated with a subsequent IL-4 production [53, 54] , indicating that a Th1 response, although critical for spirochetal eradication, can consequently contribute to tissue damage and persistent inflammation if unregulated.
Interaction of TLRs with B. burgdorferi Osps is critical in early stages of LB pathogenesis [1, 36, 55, 56] and was thought to mediate both short-and long-term disease outcomes [57] [58] [59] . A number of single-nucleotide polymorphisms (SNPs) in the TLR genes [13] and their downstream factors [60, 61] were recently proposed to modulate the host response to infection. These SNPs alter the TLR signaling patterns and may have an impact on the clinical manifestations of bacterial, fungal and viral infections [62] . For example, TLR1
Ile602Ser
was linked to elevated proinflammatory cytokine levels and a more effective Th1-like response (i.e., the microbicidal action of IFN-c) in LB patients [63] at early disease stages. TLR2 Arg753Gln polymorphism, however, provided protection against the development of late disease stage [64] . PBMCs with TLR1 Arg80Thr, Asn248Ser, and Ile602Ser and TLR6 Ser249Pro had a significantly lower synthesis of proinflammatory cytokines compared to their wild-type counterparts [65] .
(Arg753Gln) and TLR5 C1174T (Arg395Stop) were examined in patients with different LB symptoms including EM and antibiotic-responsive and refractory arthritis [63] . These SNPs were associated with decreasing numbers of plasma membrane TLRs (TLR1 T1805G and TLR2 G2258A) or with abrogation of the cellular flagellin signaling pathway (TLR5 C1174T) leading to an overall impairment of the TLR pathway and a disrupted state of cytokine synthesis [63] . Patients with antibiotic-refractory arthritis had *two-fold higher frequency of TLR1 Ile602Ser (T1805G) compared to those with EM (OR = 1.9; p = 0.05) [63] . This status of antibiotic-refractory Lyme arthritis occurs when there is persistence of synovitis for at least 3 months after antibiotic treatment, despite expulsion of viable B. burgdorferi from the affected area [65] .
Similarly, SNPs in TLR8 were proposed to lead to immunodeficiency syndromes and may be associated with an increased risk of severe clinical manifestations following B. burgdorferi infection [66, 67] . In contrast to the increased risk of Lyme arthritis associated with TLR1 Ile602Ser (T1805G), TLR2 Arg293Gln (A2258G) was shown to be protective [64] . One study demonstrated that the frequency of TLR2 Arg753Gln (A2258G) is lower in LB patients compared to matched controls (OR = 0.39, p = 0.03). In this study, patients with stage 3 LB (i.e., late persistent Lyme arthritis) had a further lower frequency of Arg753Gln (A2258G) compared to the matched controls (OR = 0.15, p = 0.003), suggesting a protective effect of TLR2 Arg293Gln in Lyme arthritis [64] . Other TLR gene polymorphisms such as TLR5 (Arg395Stop) and TLR6 (Ser249Pro) were identified to have a functional significance in host-pathogen interaction during both early and late LB stages [13, 63, 64, 68] .
In general, after initial recognition of Borrelia by TLR2/TLR1 heterodimers, the first stage in the innate immunity-related inflammation is phagocytosis. This leads to a robust proinflammatory cytokine synthesis. TLRs, known to recognize nucleic acids (e.g., TLR7, 8 and 9), might also recognize Borrelia RNA or DNA. This would result in the production of a type I IFN signature, a process to which NLRs may contribute [39] . Production of various cytokines critical to the pathogenesis of LB, e.g., IL-1b, IFN-c and IL-17, is subsequently induced. In particular, IL-1b was demonstrated to be associated with the acute and chronic inflammatory processes seen in LB [39] .
Omics Biosignature in the Early Stages of Lyme Disease
Omics technologies permit examining the differences in DNA, RNA, proteins, metabolites and other molecules between and among species. These molecular profiles may vary The differentially expressed genes at both the time of diagnosis (panel I, Fig. 1) and at 3 weeks following the completion of treatment (panel II, Fig. 1 ) were found to influence *80 different pathways, the majority of which were linked to the innate immunity-related inflammation (Fig. 1) . Analysis of the pathways modulated by these differentially expressed genes revealed activation of the inflammatory response, immune cell trafficking and hematologic system pathways.
Of the ten most altered pathways, eight were directly related to the host immune response. Specifically, the eukaryotic initiation factor 2 (eIF2) signaling pathway was downregulated at diagnosis. eIF2 signaling plays a central role in modulating translation initiation and protein synthesis and elongation in response to cellular stress [71] . Functional disruption and downregulation of the eIF2 pathway was noted with a number of intracellular bacterial pathogens [72] . However, Borrelia spirochetes do not enter cells during infection or express eIF2 inhibitors [73] . Conversely, some evidence demonstrates that B. burgdorferi can invade various cell types in vitro [74] . Therefore, it is not known whether the downregulation of the eIF2 pathway in LB patients is caused by Borrelia-mediated immune dysregulation or is simply a host response to limit tissue injury [70] . Further studies are needed to assess whether eIF2 inhibitors may be potential targets for inflammatory responses in LB as proposed previously for other pathological disorders [72] .
Transcriptional upregulation was prominent in TLR1, TLR2, TLR4, TLR7 and TLR8 during the early stages of LB, i.e., at diagnosis [70] together with a lack of activation of the inflammatory T cell apoptotic and B-cell developmental pathways [70] . This broad upregulation of the TLRs reflects a general increase in their regulatory activity rather than a direct association with B. burgdorferi proteins. In this respect, the most critical upstream regulators in LB at early stages were the proinflammatory (IFN-c, IL-1b, and TNF-a) and antiinflammatory (IL-6, IL-10) cytokines together with NF-jB and the immunoglobulin complex [70] . TNF-a was the common upstream regulator of the TLR-signaling and the TREM1 (triggering receptor expressed on myeloid cells-1)
pathway, an amplifier of the immune and inflammatory response [75] . Modulation of TREM1 impacts a number of inflammatory conditions, including septic shock and acute dengue virus infection [25, 26] were found to be differentially expressed in patients with persistent LB symptoms compared to those with resolved disease [70] .
Transcriptomics in Macrophages
The transcriptomic findings in LB patients are supported by earlier studies from mouse J774 macrophages stimulated with live B. burgdorferi spirochetes [76] . Transcriptome profiling in these cells revealed that spirochetes had significantly upregulated the expression of 347 gene transcripts and downregulated *700 others (with over a two-fold change). Among these genes, B. burgdorferi specifically altered the expression of an array of innate immunity-and inflammation-related genes to trigger the production of inflammatory mediators via recognition of TLRs (Fig. 2) . Some of these genes include chemokine (C-X-C motif) ligand genes (e.g., Cxcl2 and Cxcl10), genes that encode monocyte-derived chemokines (e.g., Ccl2, Ccl5 and Ccl9), proinflammatory cytokine genes (e.g., Tnf and ILs) and TLR genes (TLR1 [76] . Overall, the transcriptomic biosignature of the differentially expressed genes and pathways was persistent during early stages of LB infection [70, 76] . This observation was demonstrated both in vivo [70] and in vitro [76] , suggesting that a clinical diagnostic test for LB based on host gene expression can be a feasible approach for diagnosis of early disease stages. Furthermore, this approach can be employed during the period between infection and appearance of detectable antibody, a time window of a current diagnostic gap and subjectivity of clinical-based diagnosis [14, 17] .
Metabolomics in Lyme Disease Patients
Metabolomics is the analysis of the whole metabolome (low molecular weight molecules) under a given set of physiological, environmental and/or clinical conditions [20, 21, 78] . To develop a metabolic biosignature that identifies LB patients at early disease stages and classifies them from non-patients, serum samples from patients and healthy controls were recently analyzed for small molecule metabolites [14] . plasmalogens; products of tryptophan, purine and heme metabolism; an endogenous alkaloid and 7 peptides. This metabolic biosignature permitted distinguishing early LB patients from healthy controls with a sensitivity of 88% and a specificity of 95%. In this study, sera were collected from early LD patients and healthy controls. Other disease sera were also collected for metabolic biosignature comparison with LB from patients with infectious mononucleosis, fibromyalgia, severe periodontitis and syphilis.
The study revealed a shift in the abundance of selected metabolites in patients with early LD as compared to healthy controls and patients diagnosed with other diseases [14] . The majority of the putatively identified metabolites in the early LB biosignature were lipid or lipophilic structures, suggesting that B. burgdorferi infection elicits alterations in markers of the inflammatory response as well as lipid mediators [14] . This inflammatory pathway is, however, related to prostaglandin synthesis and cyclooxygenase cascades [14] rather than innate immune-associated inflammation (Fig. 3) . Since the host inflammatory responses initiated by B.
burgdorferi lead to the clinical manifestations of this disease [79], the observed metabolic profile was proposed to reflect a host response that emerges rapidly following infection. In support, innate immunity-related inflammatory markers were significantly increased in LB patients at the pre-treatment stage compared to healthy controls with no inflammatory conditions and changes were associated with greater rates of lymphopenia, elevated liver enzymes and a higher number of disease symptoms although they had higher rates of seroconversion [12] .
The findings of the differentially expressed genes and pathways identified by transcriptomics in LB patients [70] (Fig. 1 ) were consistent with those described in vitro in mouse macrophage cells [76] (Fig. 2) and were further validated by the outcome of a number of metabolic analyses in both human and cell culture models [12, 14, 76, 80 ]. In Fig. 3 Molecular features assigned putative chemical structures for the metabolic biosignature of Lyme disease [14] . The molecular features were assigned according to the number of chemical pathways related to each molecular feature. Data were extrapolated from the supplementary materials of the original study [14] mouse J774 macrophages stimulated with live B. burgdorferi, the inflammatory marker mRNA gene transcripts induced by spirochetes were examined at the protein level [76] .
Genotype-phenotype matching was observed in these cells, as the 18 cytokines/chemokines that exhibited mRNA transcript upregulation resulted in increased levels of IL-1a, IL-1b, IFN-c, CCL5 and IL-9 in stimulated macrophages compared to the unstimulated cells [76] . Furthermore, early response to live 
Inflammatomics in Lyme Disease Patients
A recent study evaluated the levels of 58 immune mediators and 7 acute phase markers from sera of patients diagnosed with acute LB and matched controls [12] . Elevated levels of monocyte-derived chemokines (CCL19, CXCL9, CXCL10), acute phase inflammatory reactants such as CRP and serum amyloid A (SAA), several IL-1 cytokine family members (IL-1Ra, IL-18, IL-33), inflammatory cytokines (TNF-a and IL-6) and the T cell cytokine IL-2 were observed in patients with acute LB. In that study, the levels of CXCL9 and CXCL10 were coordinately increased in the LB patients, particularly in a subgroup displaying an overall elevated level of inflammatory markers (see below), and was associated with induced liver enzymes [12] . It is known that EM lesions, the primary site of inflammation and bacterial replication in early LB, express high levels of CXCL9 and CXCL10 [46, 83] . Taken together, this observation and the association between CXCL9/CXCL10 levels and lymphopenia both indicate that the infection-induced tissue inflammation and chemokine production stimulate the recruitment of activated effector T cells from the blood into the site of infection [12] .
Close inspection of these findings indicated that a higher percentage of LB patients was found to have concentrations of inflammatory markers above the average levels compared to healthy controls (Fig. 4) . On the other hand, an increased percentage of healthy subjects were noted to have levels of inflammatory markers below the average values compared to LB patients (Fig. 4) . Patients with acute LB also exhibited upregulation of acute phase reactants such as CRP and SAA. CRP is a short pentraxin that acts as a fluid phase pattern recognition protein [84] whereas SAA is a serum lipoprotein that recognizes bacteria by interacting with the Osps [85] . Infection with B. burgdorferi apparently stimulates the coordinated production of CRP and SAA along with IL-6 [86, 87] and elevated serum liver enzymes during the acute stage of LB [12] . Other changes in cellular markers included decreased CD57 lymphocytes in patients with persistent LB [88] and increased C3a and C4a at 96 h following infection, i.e., during the acute disease stage [89] . Collectively, these cytokines and chemokines generate a novel signature that clearly distinguishes patients with acute LB from normal controls [12] . These observations were also noted in the mouse J774 macrophages stimulated with live B. burgdorferi spirochetes [76] 
POTENTIAL OF OMICS IN LYME DISEASE: CONCLUSION
The use of the omics approach permits the acquisition of large-scale data sets with the aim of identifying biomarkers or biosignature of a disease and/or elucidating functional or pathological mechanisms [20, 21] . This high throughput technology has been utilized recently in LB and facilitated the characterization of a distinctive disease biosignature, particularly at the early disease stages [12, 14, 70, 76] . The use of omics techniques together with targeted marker analysis have identified an array of gene transcripts and a number of secreted inflammatory mediators as candidates of a refined biosignature or biomarkers for the early recognition of LB [12, 14, 70, 76] . The low sensitivity of serologic testing in the early Fig. 4 Percentage of Lyme disease patients with modified levels of inflammatory markers compared to healthy controls [12] . Data were calculated as the percentage of subjects above or below the average level of the given inflammatory marker by determining the fold change in each Lyme disease patient (n = 44) and healthy controls (n = 23). Data were extrapolated by image analysis of the heat map presenting the levels of immune mediators in the original article [12] stages of LB is a consequence of the time it takes to develop a humoral immune response [90, 91] . In contrast, inflammation reflects the instantaneous response of the innate immune system to infection [12, 53, 54] . Omics studies facilitated the identification of a range of cytokines and chemokines along the innate immunity pathway for their role in the onset and resolution of LB [12] . Specifically, transcriptomic [70] and metabolomic [14] analyses 
